[Introduction to the Topic: Off-label Use of Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration]

Overview

Journal Ophthalmologe

Specialty Ophthalmology

Date 2006 Jun 10

PMID 16763861

Citations 6

Authors

K U Bartz-Schmidt

F G Holz

Affiliations

Soon will be listed here.

Citing Articles

Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration.

Riazi-Esfahani M, Ahmadieh H, Faghihi H, Piri N, Taei R, Karkhaneh R J Ophthalmic Vis Res. 2013; 3(2):95-101.

PMID: 23479530 PMC: 3589227.

[Intraocular injections of bevacizumab in rare indications--two cases].

Wecke T, Knop C, Schreiber W, Behrens-Baumann W Ophthalmologe. 2008; 106(5):435-42.

PMID: 18604542 DOI: 10.1007/s00347-008-1782-3.

[Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Kook D, Wolf A, Neubauer A, Haritoglou C, Priglinger S, Kampik A Ophthalmologe. 2007; 105(2):158-64.

PMID: 17653552 DOI: 10.1007/s00347-007-1561-6.

[Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks].

Lommatzsch A, Spital G, Trieschmann M, Pauleikhoff D Ophthalmologe. 2007; 104(4):325-8.

PMID: 17334745 DOI: 10.1007/s00347-006-1456-y.

Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.

Lazic R, Gabric N Graefes Arch Clin Exp Ophthalmol. 2006; 245(1):68-73.

PMID: 17111146 DOI: 10.1007/s00417-006-0466-4.

References

Senger D, Connolly D, Van de Water L, Feder J, Dvorak H . Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990; 50(6):1774-8. View

Gragoudas E, Adamis A, Cunningham Jr E, Feinsod M, Guyer D . Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27):2805-16. DOI: 10.1056/NEJMoa042760. View

Gonzales C . Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2005; 25(7):815-27. DOI: 10.1097/00006982-200510000-00001. View

Lee J, Canny M, De Erkenez A, Krilleke D, Ng Y, Shima D . A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A. 2005; 102(52):18902-7. PMC: 1323181. DOI: 10.1073/pnas.0509069102. View

Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y . VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003; 198(3):483-9. PMC: 2194095. DOI: 10.1084/jem.20022027. View